These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36226710)

  • 1. New insights into the Immune TME of adult-type diffuse gliomas.
    Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
    Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
    Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
    Picca A; Finocchiaro G
    Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
    Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct tumor-TAM interactions in IDH-stratified glioma microenvironments unveiled by single-cell and spatial transcriptomics.
    Motevasseli M; Darvishi M; Khoshnevisan A; Zeinalizadeh M; Saffar H; Bayat S; Najafi A; Abbaspour MJ; Mamivand A; Olson SB; Tabrizi M
    Acta Neuropathol Commun; 2024 Aug; 12(1):133. PubMed ID: 39148129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
    Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
    Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
    Yan D; Li W; Liu Q; Yang K
    Front Immunol; 2022; 13():914618. PubMed ID: 35769466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
    Venteicher AS; Tirosh I; Hebert C; Yizhak K; Neftel C; Filbin MG; Hovestadt V; Escalante LE; Shaw ML; Rodman C; Gillespie SM; Dionne D; Luo CC; Ravichandran H; Mylvaganam R; Mount C; Onozato ML; Nahed BV; Wakimoto H; Curry WT; Iafrate AJ; Rivera MN; Frosch MP; Golub TR; Brastianos PK; Getz G; Patel AP; Monje M; Cahill DP; Rozenblatt-Rosen O; Louis DN; Bernstein BE; Regev A; Suvà ML
    Science; 2017 Mar; 355(6332):. PubMed ID: 28360267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.
    Scholl JN; Weber AF; Dias CK; Lima VP; Grun LK; Zambonin D; Anzolin E; Dos Santos Dias WW; Kus WP; Barbé-Tuana F; Battastini AMO; Worm PV; Figueiró F
    Purinergic Signal; 2024 Feb; 20(1):47-64. PubMed ID: 36964277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
    Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
    Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.